These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 28303721

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C, Al-Saber FA, Haddad J, Jallo MK, Steitieh H, Bader G, Ibrahim M.
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, Andrews C, Barnett A.
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V, Del Prato S, Araga M, Kothny W.
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [Abstract] [Full Text] [Related]

  • 9. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C, Gautier JF.
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
    Younis A, Eskenazi D, Goldkorn R, Leor J, Naftali-Shani N, Fisman EZ, Tenenbaum A, Goldenberg I, Klempfner R.
    Cardiovasc Diabetol; 2017 May 22; 16(1):69. PubMed ID: 28532406
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G, Oh S, Jin SM, Hur KY, Kim JH, Lee MK.
    Expert Opin Pharmacother; 2017 Aug 22; 18(12):1179-1186. PubMed ID: 28714741
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I, El Kafrawy N, Raouf R, Yousry D.
    Diabetes Res Clin Pract; 2020 Apr 22; 162():108042. PubMed ID: 32006641
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A, Dejager S, Bosi E.
    Diabetes Obes Metab; 2009 Aug 22; 11(8):804-12. PubMed ID: 19476473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.